Get the Stockscreener App
295.70
0.52%
1.53
Insulet Corporation stock is traded at $295.70, with a volume of 574.66K.
It is up +0.52% in the last 24 hours and down -12.21% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$294.17
Open:
$296.08
24h Volume:
574.66K
Relative Volume:
0.88
Market Cap:
$20.80B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
89.99
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
-2.89%
1M Performance:
-12.21%
6M Performance:
-2.61%
1Y Performance:
+8.82%
1-Day Range:
$293.51
$297.48
1-Week Range:
$290.98
$306.04
52-Week Range:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
295.70 | 20.69B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Castleark Management LLC Takes Position in Insulet Corporation $PODD - MarketBeat
Engineers Gate Manager LP Acquires 96,272 Shares of Insulet Corporation $PODD - MarketBeat
Bellevue Group AG Cuts Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Occudo Quantitative Strategies LP - MarketBeat
Bayesian Capital Management LP Invests $3.90 Million in Insulet Corporation $PODD - MarketBeat
A Look Into Insulet Inc's Price Over Earnings - Benzinga
WINTON GROUP Ltd Has $1.27 Million Holdings in Insulet Corporation $PODD - MarketBeat
418,356 Shares in Insulet Corporation $PODD Purchased by Qube Research & Technologies Ltd - MarketBeat
Ossiam Sells 6,988 Shares of Insulet Corporation $PODD - MarketBeat
(PODD) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Insulet Corporation $PODD Shares Bought by California Public Employees Retirement System - MarketBeat
Here is Why Growth Investors Should Buy Insulet (PODD) Now - sharewise.com
Natixis Acquires Shares of 27,563 Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Bought by First Trust Advisors LP - MarketBeat
Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co - GuruFocus
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet Corp Director Timothy C. Stonesifer Buys 962 Shares - TradingView
Insulet Insider Bought Shares Worth $299,884, According to a Recent SEC Filing - marketscreener.com
Insulet : Appoints Cristal Downing to Newly Created Role of Chief Corporate Affairs Officer - marketscreener.com
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements - Yahoo Finance
Insulet Corporation $PODD Shares Sold by Brown Advisory Inc. - MarketBeat
Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers - Finviz
Insulet (NASDAQ:PODD) Shareholders YoY Returns Are Lagging the Company's 8.5% Five-year Earnings Growth - 富途牛牛
Federated Hermes Inc. Grows Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Jump Financial LLC - MarketBeat
FDA clears Insulet’s Omnipod 5 algorithm enhancements - MSN
Insulet gets FDA clearance for updates to Omnipod 5 automated insulin delivery - MSN
Insulet Corporation: Inside the Strategy Driving Its Robust Type 2 Adoption! - Smartkarma
Assessing Insulet’s Valuation After Omnipod Expansion and Recent Share Price Volatility - Yahoo Finance
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet (PODD) - simplywall.st
Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - marketscreener.com
Marshall Wace LLP Boosts Position in Insulet Corporation $PODD - MarketBeat
Baird Financial Group Inc. Reduces Stock Holdings in Insulet Corporation $PODD - MarketBeat
FDA clears Insulet’s enhanced Omnipod 5 insulin delivery system By Investing.com - Investing.com South Africa
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Here's Why Insulet (PODD) is a Strong Growth Stock - sharewise.com
Insulet stock price target maintained at $379 by TD Cowen on FDA clearance - Investing.com Nigeria
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option - Patient Care Online
FDA OKs Algorithm Updates to Insulet’s Omnipod 5 Insulin Pump - Medical Product Outsourcing
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - BioSpace
Insulet announces FDA 510(k) clearance of Omnipod 5 algorithm enhancements - marketscreener.com
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Insulet Announces FDA 510(K) Clearance Of Omnipod 5 Algorithm Enhancements - TradingView
Insulet Wins FDA Clearance for Updated Omnipod 5 Algorithm - marketscreener.com
Insulet (PODD) Gains FDA Clearance for Omnipod 5 System Updates - GuruFocus
FDA clears Insulet’s enhanced Omnipod 5 insulin delivery system - Investing.com
Insulet wins FDA clearance for Omnipod 5 algorithm enhancements - MassDevice
Is Insulet Corporation (GOV) stock attractive post correctionMarket Risk Summary & Technical Pattern Based Signals - Newser
Fisher Asset Management LLC Trims Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (NASDAQ:PODD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):